The assessment of pressure-volume relationship during exercise stress echocardiography predicts left ventricular remodeling and eccentric hypertrophy in patients with chronic heart failure.


Journal

Cardiovascular ultrasound
ISSN: 1476-7120
Titre abrégé: Cardiovasc Ultrasound
Pays: England
ID NLM: 101159952

Informations de publication

Date de publication:
06 Apr 2019
Historique:
received: 18 02 2019
accepted: 26 03 2019
entrez: 8 4 2019
pubmed: 8 4 2019
medline: 18 12 2019
Statut: epublish

Résumé

The contractile response of patients with heart failure (HF) may be assessed by exercise stress echocardiography (ESE)-derived indexes. We sought to test whether ESE parameters are useful to identify the risk of adverse left ventricular (LV) remodeling in patients with chronic HF and reduced or mildly reduced LV ejection fraction (EF). We enrolled 155 stabilized patients (age: 62 ± 11 years, 17% female, coronary artery disease 47%) with chronic HF, LV EF ≤50% and LV end-diastolic volume index > 75 ml/m Adverse LV remodeling was detected in 34 (22%) patients. After adjustment for clinical, biochemical and echocardiographic data, peak ESPVR resulted in the most powerful independent predictor of adverse LV remodeling (OR: 12.5 [95% CI 4.5-33]; p < 0.0001) followed by ischemic aetiology (OR: 2.64 [95% 1.04-6.73]; p = 0.04). In patients with HF and reduced or mildly reduced EF, a compromised ESE-derived peak ESPVR, that reflects impaired LV contractility, resulted to be the most powerful predictor of adverse LV remodeling.

Sections du résumé

BACKGROUND BACKGROUND
The contractile response of patients with heart failure (HF) may be assessed by exercise stress echocardiography (ESE)-derived indexes. We sought to test whether ESE parameters are useful to identify the risk of adverse left ventricular (LV) remodeling in patients with chronic HF and reduced or mildly reduced LV ejection fraction (EF).
METHODS METHODS
We enrolled 155 stabilized patients (age: 62 ± 11 years, 17% female, coronary artery disease 47%) with chronic HF, LV EF ≤50% and LV end-diastolic volume index > 75 ml/m
RESULTS RESULTS
Adverse LV remodeling was detected in 34 (22%) patients. After adjustment for clinical, biochemical and echocardiographic data, peak ESPVR resulted in the most powerful independent predictor of adverse LV remodeling (OR: 12.5 [95% CI 4.5-33]; p < 0.0001) followed by ischemic aetiology (OR: 2.64 [95% 1.04-6.73]; p = 0.04).
CONCLUSION CONCLUSIONS
In patients with HF and reduced or mildly reduced EF, a compromised ESE-derived peak ESPVR, that reflects impaired LV contractility, resulted to be the most powerful predictor of adverse LV remodeling.

Identifiants

pubmed: 30954080
doi: 10.1186/s12947-019-0157-z
pii: 10.1186/s12947-019-0157-z
pmc: PMC6451304
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6

Références

JAMA Netw Open. 2018 Aug 3;1(4):e181456
pubmed: 30646130
JACC Cardiovasc Imaging. 2011 Jan;4(1):98-108
pubmed: 21232712
J Am Soc Echocardiogr. 2009 Apr;22(4):354-60
pubmed: 19269783
Eur Heart J. 2000 Jun;21(11):927-34
pubmed: 10806017
Circ Res. 1962 Mar;10:250-8
pubmed: 14472098
Med Sci Monit. 2012 May;18(5):CR276-81
pubmed: 22534706
Eur Heart J Cardiovasc Imaging. 2016 Nov;17(11):1191-1229
pubmed: 27880640
J Am Soc Echocardiogr. 2003 Jun;16(6):646-55
pubmed: 12778025
Lancet. 2006 Jan 28;367(9507):356-67
pubmed: 16443044
Am J Cardiol. 2008 Aug 15;102(4):459-62
pubmed: 18678306
Eur J Echocardiogr. 2004 Jun;5(3):162-4
pubmed: 15147655
Eur Heart J. 2005 Nov;26(22):2404-12
pubmed: 16105848
Am J Physiol. 1991 Apr;260(4 Pt 2):H1379-84
pubmed: 1826414
Eur J Heart Fail. 2005 Mar 2;7(2):173-81
pubmed: 15701463
Circ Res. 1974 Aug;35(2):suppl II:64-70
pubmed: 4276490
Heart Fail Clin. 2019 Apr;15(2):159-166
pubmed: 30832808
J Am Soc Hypertens. 2017 Jul;11(7):412-419
pubmed: 28619598
J Am Coll Cardiol. 2000 Apr;35(5):1237-44
pubmed: 10758966
Circulation. 1987 Jul;76(1):44-51
pubmed: 3594774
J Am Coll Cardiol. 1991 Dec;18(7):1794-803
pubmed: 1960332
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Am Heart J. 2011 Jun;161(6):1088-95
pubmed: 21641355
Circ Heart Fail. 2008 May;1(1):63-71
pubmed: 19808272
Eur Heart J. 2009 Apr;30(8):950-8
pubmed: 19269987
J Card Fail. 2003 Feb;9(1):1-3
pubmed: 12612866
J Am Coll Cardiol. 2011 Oct 18;58(17):1733-40
pubmed: 21996383
Circulation. 1990 Apr;81(4):1161-72
pubmed: 2138525
Eur J Heart Fail. 2002 Jan;4(1):49-61
pubmed: 11812665
Circulation. 1994 Jan;89(1):151-63
pubmed: 8281642
Cardiovasc Ultrasound. 2005 Sep 08;3:27
pubmed: 16150150
J Am Coll Cardiol. 2000 Mar 1;35(3):569-82
pubmed: 10716457
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Circulation. 2002 Oct 29;106(18):2351-7
pubmed: 12403666
J Am Soc Echocardiogr. 2010 Dec;23(12):1259-65
pubmed: 20889309
Eur Heart J. 2014 Apr;35(16):1033-40
pubmed: 24126880

Auteurs

Iacopo Fabiani (I)

Cardiac, Thoracic and Vascular Department, University of Pisa, Pisa, Italy.
Department of Surgical, Medical, Molecular and Critical Care Pathology, Fresno, USA.

Nicola Riccardo Pugliese (NR)

Cardiac, Thoracic and Vascular Department, University of Pisa, Pisa, Italy. n.r.pugliese88@gmail.com.
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. n.r.pugliese88@gmail.com.

Claudia Santini (C)

Cardiac, Thoracic and Vascular Department, University of Pisa, Pisa, Italy.

Mario Miccoli (M)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Andreina D'Agostino (A)

Cardiac, Thoracic and Vascular Department, University of Pisa, Pisa, Italy.

Ilaria Rovai (I)

Cardiac, Thoracic and Vascular Department, University of Pisa, Pisa, Italy.

Matteo Mazzola (M)

Cardiac, Thoracic and Vascular Department, University of Pisa, Pisa, Italy.

Roberto Pedrinelli (R)

Cardiac, Thoracic and Vascular Department, University of Pisa, Pisa, Italy.

Frank Lloyd Dini (FL)

Cardiac, Thoracic and Vascular Department, University of Pisa, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH